Cargando…

Imaging the L-Type Amino Acid Transporter-1 (LAT1) with Zr-89 ImmunoPET

The L-type amino acid transporter-1 (LAT1, SLC7A5) is upregulated in a wide range of human cancers, positively correlated with the biological aggressiveness of tumors, and a promising target for both imaging and therapy. Radiolabeled amino acids such as O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET) that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikotun, Oluwatayo F., Marquez, Bernadette V., Huang, Chaofeng, Masuko, Kazue, Daiji, Miyamoto, Masuko, Takashi, McConathy, Jonathan, Lapi, Suzanne E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797081/ https://www.ncbi.nlm.nih.gov/pubmed/24143237 http://dx.doi.org/10.1371/journal.pone.0077476

Ejemplares similares

Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
por: Marquez, Bernadette V., et al.
Publicado: (2014)

(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
por: Chekol, Rufael, et al.
Publicado: (2018)

(89)Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe
por: Fung, Kimberly, et al.
Publicado: (2020)

Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
por: Hagens, Marloes HJ, et al.
Publicado: (2017)

Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET
por: Raavé, René, et al.
Publicado: (2019)

(89)Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas
por: Herrero Alvarez, Natalia, et al.
Publicado: (2023)

Additional information on “Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET”
por: Raavé, René, et al.
Publicado: (2019)

Improved image reconstruction of (89)Zr-immunoPET studies using a Bayesian penalized likelihood reconstruction algorithm
por: Kirchner, Julian, et al.
Publicado: (2021)

Optimisation of scan duration and image quality in oncological (89)Zr immunoPET imaging using the Biograph Vision PET/CT
por: van Sluis, Joyce, et al.
Publicado: (2023)

First-in-human immunoPET imaging of HIV-1 infection using (89)Zr-labeled VRC01 broadly neutralizing antibody
por: Beckford-Vera, Denis R., et al.
Publicado: (2022)

(89)Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo
por: Alizadeh, Elahe, et al.
Publicado: (2021)

Imaging PD-L1 Expression with ImmunoPET
por: Truillet, Charles, et al.
Publicado: (2017)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Anti‐tumor effects of mAb against l‐type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes
por: Ueda, Shiho, et al.
Publicado: (2019)

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors
por: Manafi-Farid, Reyhaneh, et al.
Publicado: (2022)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas
por: de Lucas, A. G., et al.
Publicado: (2016)

Detection of Rapalog-Mediated Therapeutic Response in Renal Cancer Xenografts Using (64)Cu-bevacizumab ImmunoPET
por: Chang, Albert J., et al.
Publicado: (2013)

Visualizing Galectin-3 Binding Protein Expression with ImmunoPET
por: Keinänen, Outi, et al.
Publicado: (2023)

Editorial: ImmunoPET imaging in disease diagnosis and therapy assessment
por: Mulero, Francisca
Publicado: (2023)

ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer
por: Li, Ziqi, et al.
Publicado: (2023)

Pre-clinical Imaging of Invasive Candidiasis Using ImmunoPET/MR
por: Morad, Hassan O. J., et al.
Publicado: (2018)

ImmunoPET in Multiple Myeloma—What? So What? Now What?
por: Bailly, Clément, et al.
Publicado: (2020)

Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice
por: Meyblum, Louis, et al.
Publicado: (2023)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

Development of (89)Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications
por: Lange, Sara E.S., et al.
Publicado: (2016)

Generation and Screening of Monoclonal Antibodies for ImmunoPET Imaging of IGF1R in Prostate Cancer
por: Hong, Hao, et al.
Publicado: (2014)

ImmunoPET to help stratify patients for targeted therapies and to improve drug development
por: Kraeber-Bodere, Françoise, et al.
Publicado: (2016)

Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications
por: Fu, Ruisi, et al.
Publicado: (2018)

Tissue Factor‐Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer
por: Wei, Weijun, et al.
Publicado: (2020)

ImmunoPET Directed to the Brain: A New Tool for Preclinical and Clinical Neuroscience
por: de Lucas, Ángel García, et al.
Publicado: (2023)

Development of [(89)Zr]Zr-hCD103.Fab01A and [(68)Ga]Ga-hCD103.Fab01A for PET imaging to noninvasively assess cancer reactive T cell infiltration: Fab-based CD103 immunoPET
por: Fan, Xiaoyu, et al.
Publicado: (2023)

Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for (89)Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice
por: N.Tinianow, Jeff, et al.
Publicado: (2016)

ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1
por: Williams, Simon-Peter, et al.
Publicado: (2016)

Immuno-PET Imaging of Atherosclerotic Plaques with [(89)Zr]Zr-Anti-CD40 mAb—Proof of Concept
por: Poels, Kikkie, et al.
Publicado: (2022)

Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis
por: Jauw, Yvonne W. S., et al.
Publicado: (2019)

Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model
por: Escorcia, Freddy E., et al.
Publicado: (2018)

Noise sensitivity of (89)Zr-Immuno-PET radiomics based on count-reduced clinical images
por: Somasundaram, Ananthi, et al.
Publicado: (2022)

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with (89)Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol
por: Hegi-Johnson, Fiona, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lpe7o0l1autpq39b76893jftte